Hepatocyte Growth Factor: A Possible Mediator of Heparin-induced Osteoporosis?

1. Kock HJ , Handschin AE. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation. Clin Appl Thromb Hemost 2002;8:251-251.

2. Zarnegar R , Michalopoulos GK. The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. J Cell Biol 1995;129:1177-1177.

3. Grano M , Galimi F , Zambonin G , et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1993;93:7644-7644.

4. Sato T , Hakeda Y , Yamaguchi Y , et al. Hepatocyte growth factor is involved in formation of osteoclasts-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol 1995;164:197-197.

5. Fuller K , Chambers TJ , Gallagher AC. Heparin augments osteoclasts resorption-stimulating activity in serum. J Cell Physiol 1991;147:208-208.

6. Fuller K , Owens J , Chambers TJ. The effect of hepatocyte growth factor on the behaviour of osteoclasts. Biochem Biophys Res Commun 1995;212:334-334.

7. Matsumori A , Ono K , Okada M , et al. Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin. J Mol Cell Cardiol 1998;30:2145-2145.

8. Okada M , Matsumori A , Ono K , et al. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 1999;255:80-80.

9. Salbach PB , Bruckmann M , Turovets O , et al. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 2000;50:221-221.

10. Seidel C , Hjorth-Hansen H , Bendz B , et al. Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol 1999;105:641-641.

11. Taal MW , Masud T , Green D , et al. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999;14:1922-1922.

12. Gupta A , Kallenbach LR , Divine GW. Increased risk of hip fractures in U.S. Medicare end-stage renal disease patients. J Bone Miner Res 1997;12(suppl 1):274-274.

13. Lai KN , Ho K , Cheung RC , Lit LC , et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int JArtif Organs 2001;24:447-447.

14. Borawski J , Mys'liwiec M. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients. Nephrol Dial Transplant 2002;17:637-637.

15. Borawski J , Pawlak K , Naumnik B , et al. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients. Renal Failure (in press).